★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Hims & Hers Health, Inc. (HIMS) Moat Analysis
Hims & Hers Health, Inc.
HIMS · New York Stock Exchange
Partial score covering 87% of segment weight.
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Hims & Hers Health is a D2C digital health company whose revenue is reported by geography. Its June 2, 2026 acquisition of Eucalyptus expanded the international footprint into Australia and Japan and deepened operations in the UK, Germany and Canada, but the Q1 segment shares predate that transaction. The only retained U.S. advantage is a modest integrated-operating capability from its platform, provider coordination and licensed pharmacy fulfillment. Subscription auto-renewal, subscriber scale and management assertions about brand importance do not by themselves establish durable switching costs or brand power. Competition is intense, switching friction is limited, and FDA scrutiny of compounded GLP-1 drugs is a material regulatory risk.
Primary segment
United States Platform
Market structure
Competitive
Market share
—
HHI: —
Coverage
2 segments · 6 tags
Updated 2026-07-12
Segments
United States Platform
Direct-to-consumer telehealth + subscription pharmacy (cash-pay) for lifestyle and chronic conditions
Revenue
87.1%
Structure
Competitive
Pricing
weak
Share
—
Peers
Rest of World Platform
Direct-to-consumer digital health and pharmacy/fulfillment platform outside the United States
Revenue
12.9%
Structure
Competitive
Pricing
weak
Share
—
Peers
Moat Claims
United States Platform
Direct-to-consumer telehealth + subscription pharmacy (cash-pay) for lifestyle and chronic conditions
Revenue share computed from Q1 2026 United States revenue ($529.9M) divided by total revenue ($608.1M). FY2025 Form 10-K states Online/Wholesale became less relevant and the company is moving to United States/Rest of World revenue disaggregation.
Operational Excellence
Supply
Operational Excellence
Strength
Durability
Confidence
Evidence
End-to-end operating capability (platform + provider network coordination + fulfillment) can reduce cost-to-serve and improve the customer experience versus a more fragmented model reliant on third parties.
Operational Excellence moat: definition, examples, and stocks
Erosion risks
- Operational disruption (fulfillment errors, delays, quality failures)
- FDA restrictions or enforcement affecting compounded GLP-1 drugs and related marketing
- Scale advantage competed away if large incumbents match execution
Leading indicators
- Gross margin trend (especially as mix shifts)
- Delivery time SLAs and pharmacy fulfillment error rates
- Customer support contact rate per order/subscriber
Counterarguments
- Operational playbooks can be copied; fulfillment scale can be purchased via 3P logistics/pharmacy networks
- Incumbent retailers and Amazon can out-scale on logistics and supply chain
Rest of World Platform
Direct-to-consumer digital health and pharmacy/fulfillment platform outside the United States
Revenue share is computed from Q1 2026 Rest of World revenue ($78.2M) divided by total revenue ($608.1M) and therefore predates the June 2, 2026 closing of the Eucalyptus acquisition. Eucalyptus adds operations in Australia and Japan and expands the UK, Germany, and Canada footprint; no post-close segment results are yet available.
Insufficient segment-specific evidence to assign a moat claim.
Evidence
enable seamless drug delivery and supply chain oversight
Supports a supply-side advantage claim: integrated fulfillment capabilities can improve delivery experience and reduce reliance on third-party pharmacy contracts.
two licensed 503A pharmacies and two pharmacies licensed by the UK General Pharmaceutical Council
Owned/licensed facilities support operational control over fulfillment and service levels.
Risks & Indicators
Erosion risks
- Operational disruption (fulfillment errors, delays, quality failures)
- FDA restrictions or enforcement affecting compounded GLP-1 drugs and related marketing
- Scale advantage competed away if large incumbents match execution
Leading indicators
- Gross margin trend (especially as mix shifts)
- Delivery time SLAs and pharmacy fulfillment error rates
- Customer support contact rate per order/subscriber
- Cost of revenue per shipment
Research HIMS elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.